Cystic fibrosis: terminology and diagnostic algorithms

被引:240
作者
De Boeck, K.
Wilschanski, M.
Castellani, C.
Taylor, C.
Cuppens, H.
Dodge, J.
Sinaasappel, M.
机构
[1] Catholic Univ Louvain, Dept Pediat, B-3000 Louvain, Belgium
[2] Hadassah Med Org, Dept Pediat Gastroenterol, Jerusalem, Israel
[3] Osped Civile, CF Ctr, I-37126 Verona, Italy
[4] Univ Sheffield, Acad Unit Child Hlth, Sheffield S10 2TN, S Yorkshire, England
[5] Catholic Univ Louvain, Dept Human Genet, B-3000 Louvain, Belgium
[6] Univ Coll Swansea, Dept Child Hlth, Swansea, W Glam, Wales
[7] Univ Med Ctr, Erasmus MC Sophia Childrens Hosp, Dept Pediat, Rotterdam, Netherlands
关键词
D O I
10.1136/thx.2005.043539
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
There is great heterogeneity in the clinical manifestations of cystic fibrosis (CF). Some patients may have all the classical manifestations of CF from infancy and have a relatively poor prognosis, while others have much milder or even atypical disease manifestations and still carry mutations on each of the CFTR genes. It is important to distinguish between these categories of patients. The European Diagnostic Working Group proposes the following terminology. Patients are diagnosed with classic or typical CF if they have one or more phenotypic characteristics and a sweat chloride concentration of > 60 mmol/l. The vast majority of CF patients fall into this category. Usually one established mutation causing CF can be identified on each CFTR gene. Patients with classic CF can have exocrine pancreatic insufficiency or pancreatic sufficiency. The disease can have a severe course with rapid progression of symptoms or a milder course with very little deterioration over time. Patients with non-classic or atypical CF have a CF phenotype in at least one organ system and a normal (< 30 mmol/l) or borderline (30-60 mmol/l) sweat chloride level. In these patients confirmation of the diagnosis of CF requires detection of one disease causing mutation on each CFTR gene or direct quantification of CFTR dysfunction by nasal potential difference measurement. Non-classic CF includes patients with multiorgan or single organ involvement. Most of these patients have exocrine pancreatic sufficiency and milder lung disease. Algorithms for a structured diagnostic process are proposed.
引用
收藏
页码:627 / 635
页数:9
相关论文
共 43 条
[1]   Genomic rearrangements in the CFTR gene:: Extensive allelic heterogeneity and diverse mutational mechanisms [J].
Audrézet, M ;
Chen, JM ;
Raguénès, O ;
Chuzhanova, N ;
Giteau, K ;
Le Maréchal, C ;
Quéré, I ;
Cooper, DN ;
Férec, C .
HUMAN MUTATION, 2004, 23 (04) :343-357
[2]   Regulation of airway surface liquid volume by human airway epithelia [J].
Boucher, RC .
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2003, 445 (04) :495-498
[3]   Nonclassic cystic fibrosis and CFTR-related diseases [J].
Boyle, MP .
CURRENT OPINION IN PULMONARY MEDICINE, 2003, 9 (06) :498-503
[4]   MUTATIONS IN THE CYSTIC-FIBROSIS GENE IN PATIENTS WITH CONGENITAL ABSENCE OF THE VAS-DEFERENS [J].
CHILLON, M ;
CASALS, T ;
MERCIER, B ;
BASSAS, L ;
LISSENS, W ;
SILBER, S ;
ROMEY, MC ;
RUIZROMERO, J ;
VERLINGUE, C ;
CLAUSTRES, M ;
NUNES, V ;
FEREC, C ;
ESTIVILL, X .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (22) :1475-1480
[5]   THE GENETIC TESTING OF CHILDREN [J].
CLARKE, A .
JOURNAL OF MEDICAL GENETICS, 1994, 31 (10) :785-797
[6]   NEONATAL SCREENING FOR CYSTIC-FIBROSIS, USING IMMUNOREACTIVE TRYPSIN ASSAY IN DRIED BLOOD SPOTS [J].
CROSSLEY, JR ;
SMITH, PA ;
EDGAR, BW ;
GLUCKMAN, PD ;
ELLIOTT, RB .
CLINICA CHIMICA ACTA, 1981, 113 (02) :111-121
[7]   DETECTION OF 98.5-PERCENT OF THE MUTATIONS IN 200 BELGIAN CYSTIC-FIBROSIS ALLELES BY REVERSE DOT-BLOT AND SEQUENCING OF THE COMPLETE CODING REGION AND EXON/INTRON JUNCTIONS OF THE CFTR GENE [J].
CUPPENS, H ;
MARYNEN, P ;
DEBOECK, C ;
CASSIMAN, JJ .
GENOMICS, 1993, 18 (03) :693-697
[8]   Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes - The polymorphic (TG)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation [J].
Cuppens, H ;
Lin, W ;
Jaspers, M ;
Costes, B ;
Teng, H ;
Vankeerberghen, A ;
Jorissen, M ;
Droogmans, G ;
Reynaert, I ;
Goossens, M ;
Nilius, B ;
Cassiman, JJ .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (02) :487-496
[9]  
Davies J, 2005, J ROY SOC MED, V98, P47
[10]  
De Jonge Hugo R, 2004, J Cyst Fibros, V3 Suppl 2, P159, DOI 10.1016/j.jcf.2004.05.034